Showing results (91-100 of 186) with videos related to

Sort By:
Pageof 19
Plos One|June 27, 2014
In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patientsMaria Vassilakopoulou, Taiwo Togun, Urania Dafni, et al.
Anticancer Research|January 25, 2008
Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patientsEleni Timotheadou, Dimosthenis-Vasilios Skarlos, Epaminondas Samantas, et al.
The New England Journal of Medicine|February 17, 2006
Prognostic significance of autoimmunity during treatment of melanoma with interferonHelen Gogas, John Ioannovich, Urania Dafni, et al.
Molecular and Clinical Oncology|February 20, 2016
Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemiaGiannis Mountzios, Gerasimos Aravantinos, Zoi Alexopoulou, et al.
Clinical Colorectal Cancer|December 26, 2015
Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant OxaliplatinStacey A Cohen, Chen Wu, Ming Yu, et al.
Anticancer Research|November 27, 2008
Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology GroupAngelos K Koutras, George Fountzilas, Urania Dafni, et al.
Plos One|August 13, 2013
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trialGeorge Fountzilas, Vassiliki Kotoula, Dimitrios Pectasides, et al.
BMC Medicine|January 9, 2010
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group studyDimitrios Bafaloukos, Helena Linardou, Gerasimos Aravantinos, et al.
BMC Clinical Pathology|July 3, 2014
alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studiesTriantafyllia Koletsa, Flora Stavridi, Mattheos Bobos, et al.
Breast Cancer Research and Treatment|March 11, 2011
Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) studyGeorge Pentheroudakis, Anna Batistatou, Konstantine T Kalogeras, et al.
Pageof 19